École Polytechnique Fédérale de Lausanne (EPFL) spin-out Anokion has successfully closed its series A at CHF33m ($37.5m), with investors including life sciences venture capitalists Novartis Venture Fund, Novo Ventures and Versant Ventures, which together led the financing with additional participation by private investors.
Anokion will use the funds to develop clinical candidates in the areas of immune-masked protein therapeutics, auto-immune and allergic diseases. The company is also looking at adapting its technology to prevent immune reactions to protein drugs used to…